Hans-Peter Gerber
University of Zurich
CancerInternal medicineEndocrinologyVascular endothelial growth factor AVascular endothelial growth factor BMolecular biologyAntibodyReceptorChemistryConjugateImmunologyIn vivoVascular endothelial growth factorBevacizumabNeovascularizationAngiogenesisCancer researchMonoclonal antibodyMedicineBiologyCell biologyPharmacology
105Publications
60H-index
32.3kCitations
Publications 104
Newest
#1Matthew Sung (Pfizer)H-Index: 9
#2Christine Hopf (Pfizer)
Last. Edward Rosfjord (Pfizer)H-Index: 19
view all 14 authors...
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice and represent personalized murine ‘avatars9 of those tumors. PDXs are valuable tumor models for drug development since they recapitulate the complexity of the human tumor microenvironment more extensively than cell line xenografts (CLXs). Unlike CLXs, PDXs are never passaged in vitro, and therefore they more faithfully recapitulate native tumor biology and response to therapeutics. Thus, PDXs may more accurately pred...
Source
#1Yoon-Chi Han (Pfizer)H-Index: 1
#2Fan Jiang (Pfizer)H-Index: 1
Last. Puja Sapra (Pfizer)H-Index: 19
view all 19 authors...
CD123 is expressed on cancer cells in a variety of hematologic malignancies including acute myeloid leukemia (AML). CD123 is frequently expressed on leukemic blasts and leukemic stem cells (LSCs), a cell population associated with relapse in patients, but there is minimal or no expression on most normal hematopoietic cells and solid tissues. Thus, CD123 is a promising target for AML. We have generated an anti-CD123 ADC that carries cyclopropylpyrroloindoline (CPI) payload that crosslinks DNA. A ...
1 CitationsSource
#1Matthew Sung (Pfizer)H-Index: 9
#2Xingzhi Tan (Pfizer)H-Index: 10
Last. Frank Loganzo (Pfizer)H-Index: 17
view all 15 authors...
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that has demonstrated clinical benefit for patients with HER2+ metastatic breast cancer, however its clinical activity is limited by inherent or acquired drug resistance. The molecular mechanisms that drive clinical resistance to T-DM1, especially in HER2+ tumors, are not well understood. We used HER2+ cell lines to develop models of T-DM1 resistance utilizing a cyclical dosing schema in which cells received T-DM1 in an "on-off" r...
44 CitationsSource
#1L. Nathan Tumey (Binghamton University)H-Index: 20
#2Fengping Li (Pfizer)H-Index: 4
Last. Lioudmila Tchistiakova (Pfizer)H-Index: 24
view all 19 authors...
As the antibody drug conjugate (ADC) community continues to shift towards site-specific conjugation technology, there is a growing need to understand how the site of conjugation impacts the biophysical and biological properties of an ADC. In order to address this need, we prepared a carefully selected series of engineered cysteine ADCs and proceeded to systematically evaluate their potency, stability, and PK exposure. The site of conjugation did not have a significant influence on the thermal st...
23 CitationsSource
Using an expanded genetic code, antibodies with site-specifically incorporated nonnative amino acids were produced in stable cell lines derived from a CHO cell line with titers over 1 g/L. Using anti-5T4 and anti-Her2 antibodies as model systems, site-specific antibody drug conjugates (NDCs) were produced, via oxime bond formation between ketones on the side chain of the incorporated nonnative amino acid and hydroxylamine functionalized monomethyl auristatin D with either protease-cleavable or n...
201 CitationsSource
#1Andreas MadernaH-Index: 11
Last. D MaH-Index: 1
view all 40 authors...
1 Citations
#1Puja Sapra (U of A: University of Alberta)H-Index: 15
#2John Dijoseph (RU: Rutgers University)H-Index: 1
Last. Hans-Peter Gerber (UZH: University of Zurich)H-Index: 60
view all 3 authors...
3 CitationsSource
Vascular endothelial growth factor A (VEGF-A) is a well-characterized regulator of physiological and pathological angiogenesis. Multiple therapeutic compounds interfering with VEGF-A-regulated signal transduction pathways are currently being developed for the treatment of neoplasias and other malignancies associated with pathological angiogenesis. A major challenge in developing anti-VEGF therapies are tumor intrinsic refractoriness and the emergence of treatment-induced resistance. A variety of...
11 CitationsSource
#1Lacy Susan EH-Index: 7
Last. Janice M. ReichertH-Index: 44
view all 6 authors...
The Americas Antibody Congress, organized by Terrapinn, was held in Washington, D.C. on September 21-23, 2009. The conference sessions were expertly moderated by Herren Wu (MedImmune), and featured 26 speakers who discussed a wide variety of topics relevant to antibody research and development. In addition to the presentations, the conference included four panel sessions during which unscripted dialog between panelist and the audience was encouraged. The topics of the panel sessions were: (1) id...
3 CitationsSource
#1Ezogelin Oflazoglu (Seattle Genetics)H-Index: 14
#2Tamar E. BoursalianH-Index: 11
Last. Iqbal S. GrewalH-Index: 50
view all 9 authors...
Rheumatoid arthritis (RA) is characterized by inflammation and cellular proliferation in the synovial lining of joints that result in cartilage and bone destruction. Although the etiology of RA is unclear, activated lymphocytes and proinflammatory molecules, in particular TNF superfamily members, have been implicated in the disease pathology. A TNF superfamily member, CD70, is found on activated lymphocytes and shown to be important in memory and effector responses of lymphocytes. CD70 is expres...
68 CitationsSource